Cite
26 - Phase 1 Study of Elotuzumab in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma.
MLA
Osman, Keren, et al. “26 - Phase 1 Study of Elotuzumab in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma.” Biology of Blood & Marrow Transplantation, vol. 24, Mar. 2018, pp. S49–50. EBSCOhost, https://doi.org/10.1016/j.bbmt.2017.12.601.
APA
Osman, K., Chari, A., Parekh, S. S., Caro, J., Aleman, A., Mandeli, J., Jagannath, S., & Cho, H. J. (2018). 26 - Phase 1 Study of Elotuzumab in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma. Biology of Blood & Marrow Transplantation, 24, S49–S50. https://doi.org/10.1016/j.bbmt.2017.12.601
Chicago
Osman, Keren, Ajai Chari, Samir Sunil Parekh, Jessica Caro, Adolfo Aleman, John Mandeli, Sundar Jagannath, and Hearn Jay Cho. 2018. “26 - Phase 1 Study of Elotuzumab in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma.” Biology of Blood & Marrow Transplantation 24 (March): S49–50. doi:10.1016/j.bbmt.2017.12.601.